1. Home
  2. REGN
  3. REGN News

Latest Regeneron Pharmaceuticals Inc. (REGN) News on May 11, 2025

Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports Q1 2025 Revenue Drop to US$3,029 Million
REGN

Simply Wall St.

a day ago

Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports Q1 2025 Revenue Drop to US$3,029 Million

Is Regeneron Pharmaceuticals, Inc. (REGN) the Worst Blue Chip Stock to Buy?
REGN

Insider Monkey

a day ago

Is Regeneron Pharmaceuticals, Inc. (REGN) the Worst Blue Chip Stock to Buy?

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Numbers Came Up A Little Short’
REGN

Insider Monkey

2 days ago

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Numbers Came Up A Little Short’

1 Cash-Heavy Stock on Our Buy List and 2 to Ignore
REGN

StockStory

2 days ago

1 Cash-Heavy Stock on Our Buy List and 2 to Ignore

Regeneron Pharmaceuticals, Inc. (REGN): Among the Cheap ESG Stocks to Buy According to Hedge Funds
REGN

Insider Monkey

3 days ago

Regeneron Pharmaceuticals, Inc. (REGN): Among the Cheap ESG Stocks to Buy According to Hedge Funds

Regeneron Pharmaceuticals (REGN): Among Billionaire Mario Gabelli’s Large-Cap Stock Picks with Huge Upside Potential
REGN

Insider Monkey

4 days ago

Regeneron Pharmaceuticals (REGN): Among Billionaire Mario Gabelli’s Large-Cap Stock Picks with Huge Upside Potential

Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y
REGN

Zacks

9 days ago

Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’
REGN

Insider Monkey

10 days ago

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’

Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences
REGN

Simply Wall St.

10 days ago

Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences

Regeneron price target lowered to $940 from $975 at Truist
REGN

TipRanks

10 days ago

Regeneron price target lowered to $940 from $975 at Truist

Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
REGN

GlobeNewswire

10 days ago

Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination

Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases
REGN

GlobeNewswire

10 days ago

Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases

REGN

MT Newswires

11 days ago

Guggenheim Cuts Regeneron Pharmaceuticals' Price Target to $810 From $940

REGN

Morningstar Research

11 days ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

REGN

MT Newswires

11 days ago

Goldman Cuts Regeneron Pharmaceuticals' Price Target to $804 From $917

REGN

MT Newswires

11 days ago

BMO Cuts Regeneron Pharmaceuticals' Price Target to $800 From $865

REGN

MT Newswires

11 days ago

Evercore ISI Cuts Regeneron Pharmaceuticals' Price Target to $900 From $950

REGN

MT Newswires

11 days ago

Leerink Partners Cuts Regeneron Pharmaceuticals' Price Target to $686 From $780

REGN

MT Newswires

11 days ago

RBC Cuts Price Target on Regeneron Pharmaceuticals to $943 From $1,051, Keeps Outperform Rating

Regeneron Pharmaceuticals First Quarter 2025 Earnings: Revenues Disappoint
REGN

Simply Wall St.

11 days ago

Regeneron Pharmaceuticals First Quarter 2025 Earnings: Revenues Disappoint

REGN

MT Newswires

11 days ago

Truist Cuts Price Target on Regeneron Pharmaceuticals to $940 From $975, Keeps Buy Rating

Regeneron Pharmaceuticals Inc (REGN) Q1 2025 Earnings Call Highlights: Strong Dupixent Sales ...
REGN

GuruFocus.com

11 days ago

Regeneron Pharmaceuticals Inc (REGN) Q1 2025 Earnings Call Highlights: Strong Dupixent Sales ...

REGN

Thomson Reuters StreetEvents

11 days ago

Q1 2025 Regeneron Pharmaceuticals Inc Earnings Call

Regeneron Crashes 7% After Eylea Miss Drags Its Earnings Down
REGN

Investor's Business Daily

12 days ago

Regeneron Crashes 7% After Eylea Miss Drags Its Earnings Down

REGN

MT Newswires

12 days ago

Equity Markets Higher Despite Weak US Consumer Confidence Data

Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides
REGN

Benzinga

12 days ago

Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides

Regeneron Crashes 10% After Eylea Miss Drags Its Earnings Report
REGN

Investor's Business Daily

12 days ago

Regeneron Crashes 10% After Eylea Miss Drags Its Earnings Report

REGN

MT Newswires

12 days ago

Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday

Regeneron Stock Plummets After Earnings Miss
REGN

Barrons.com

12 days ago

Regeneron Stock Plummets After Earnings Miss

Regeneron Pharma's first-quarter results miss on lower Eylea demand
REGN

Reuters

12 days ago

Regeneron Pharma's first-quarter results miss on lower Eylea demand

Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates
REGN

Zacks

12 days ago

Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates

REGN

Associated Press Finance

12 days ago

Regeneron: Q1 Earnings Snapshot

Regeneron (NASDAQ:REGN) Misses Q1 Sales Targets
REGN

StockStory

12 days ago

Regeneron (NASDAQ:REGN) Misses Q1 Sales Targets

REGN

MT Newswires

12 days ago

Regeneron Pharmaceuticals' Q1 Adjusted Earnings, Revenue Fall

REGN

MT Newswires

13 days ago

Regeneron Pharmaceuticals' Lynozyfic Receives Conditional Approval in Europe for Multiple Myeloma

Regeneron expands US manufacturing with $3B Fujifilm partnership
REGN

Manufacturing Dive

13 days ago

Regeneron expands US manufacturing with $3B Fujifilm partnership

Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
REGN

GlobeNewswire

13 days ago

Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma

EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease
REGN

GlobeNewswire

13 days ago

EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease

Regeneron (REGN) Reports Earnings Tomorrow: What To Expect
REGN

StockStory

13 days ago

Regeneron (REGN) Reports Earnings Tomorrow: What To Expect

Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold
REGN

Motley Fool

15 days ago

Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold

REGN

MT Newswires

16 days ago

Evercore ISI Adjusts Regeneron Pharmaceuticals PT to $950 From $1,000, Maintains Outperform Rating

REGN

MT Newswires

17 days ago

Baird Cuts Price Target on Regeneron Pharmaceuticals to $652 From $759

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
REGN

Zacks

17 days ago

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

What Analyst Projections for Key Metrics Reveal About Regeneron (REGN) Q1 Earnings
REGN

Zacks

17 days ago

What Analyst Projections for Key Metrics Reveal About Regeneron (REGN) Q1 Earnings

Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More
REGN

Zacks

18 days ago

Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More

REGN

MT Newswires

18 days ago

Truist Adjusts Price Target on Regeneron Pharmaceuticals to $975 From $1,004, Maintains Buy Rating

REGN

MT Newswires

18 days ago

TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $970, Maintains Buy Rating

REGN

MT Newswires

18 days ago

Wells Fargo Adjusts Price Target on Regeneron Pharmaceuticals to $750 From $900, Maintains Overweight Rating

REGN

MT Newswires

18 days ago

Truist Cuts Price Target on Regeneron Pharmaceuticals to $975 From $1,004, Keeps Buy Rating

Regeneron to Report Q1 Earnings: What's in Store for the Stock?
REGN

Zacks

19 days ago

Regeneron to Report Q1 Earnings: What's in Store for the Stock?

Regeneron Pharmaceuticals (NasdaqGS:REGN) Expands U.S. Capacity With US$3 Billion Fujifilm Partnership
REGN

Simply Wall St.

19 days ago

Regeneron Pharmaceuticals (NasdaqGS:REGN) Expands U.S. Capacity With US$3 Billion Fujifilm Partnership

Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom
REGN

Barrons.com

19 days ago

Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom

Regeneron partners with Fujifilm to broaden manufacturing capacity
REGN

Pharmaceutical Technology

19 days ago

Regeneron partners with Fujifilm to broaden manufacturing capacity

Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for
REGN

Zacks

19 days ago

Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for

REGN

MT Newswires

19 days ago

Canaccord Genuity Adjusts Price Target on Regeneron Pharmaceuticals to $850 From $1,152, Maintains Buy Rating

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs
REGN

The Wall Street Journal

19 days ago

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs

REGN

MT Newswires

20 days ago

Sector Update: Health Care

REGN

MT Newswires

20 days ago

FDA Approves Dupixent for Chronic Hives in Patients Unresponsive to Antihistamines

REGN

MT Newswires

20 days ago

Regeneron Pharmaceuticals Says FDA Rejects Bid for Extended Eye Drug Dosing Intervals

Sanofi and Regeneron’s dupilumab approved by FDA for urticaria
REGN

Pharmaceutical Technology

20 days ago

Sanofi and Regeneron’s dupilumab approved by FDA for urticaria

Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD
REGN

TipRanks

22 days ago

Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD

Regeneron, Sanofi announce FDA approval of Dupixent for CSU
REGN

TipRanks

22 days ago

Regeneron, Sanofi announce FDA approval of Dupixent for CSU

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
REGN

GlobeNewswire

23 days ago

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
REGN

GlobeNewswire

23 days ago

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Sanofi, Regeneron win FDA nod for Dupixent in chronic hives
REGN

BioPharma Dive

23 days ago

Sanofi, Regeneron win FDA nod for Dupixent in chronic hives

REGN

MT Newswires

24 days ago

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $865 From $903

FDA to review Regeneron’s sBLA for aflibercept injection 8mg
REGN

Pharmaceutical Technology

24 days ago

FDA to review Regeneron’s sBLA for aflibercept injection 8mg

REGN

MT Newswires

24 days ago

Regeneron Says Application for Expanded Use of Eylea Accepted for FDA Priority Review

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
REGN

GlobeNewswire

24 days ago

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
REGN

StockStory

a month ago

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
REGN

StockStory

a month ago

Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

REGN

MT Newswires

a month ago

Citigroup Adjusts Price Target on Regeneron Pharmaceuticals to $600 From $750, Keeps Neutral Rating

REGN

MT Newswires

a month ago

Goldman Sachs Cuts Price Target on Regeneron Pharmaceuticals to $917 From $1,019, Keeps Buy Rating

REGN

Morningstar Research

a month ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

REGN

MT Newswires

a month ago

Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $940 From $950, Maintains Buy Rating

REGN

MT Newswires

a month ago

Morgan Stanley Adjusts PT on Regeneron Pharmaceuticals to $1,081 From $1,150, Keeps Overweight Rating

REGN

MT Newswires

a month ago

Jefferies Adjusts Regeneron Pharmaceuticals' Price Target to $936 rom $1,120, Keeps Buy Rating

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
REGN

Motley Fool

a month ago

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
REGN

StockStory

a month ago

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

Regeneron Pharmaceuticals (NasdaqGS:REGN) Drops 10% Over Last Week Despite Dupixent Approval in Japan
REGN

Simply Wall St.

a month ago

Regeneron Pharmaceuticals (NasdaqGS:REGN) Drops 10% Over Last Week Despite Dupixent Approval in Japan

3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years
REGN

Motley Fool

a month ago

3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years

REGN

MT Newswires

a month ago

Oppenheimer Adjusts PT on Regeneron Pharmaceuticals to $925 From $950, Maintains Outperform Rating

REGN

MT Newswires

a month ago

RBC Raises Price Target on Regeneron Pharmaceuticals to $1,051 From $1,045, Keeps Outperform Rating

REGN

MT Newswires

a month ago

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $979 From $1,010, Maintains Outperform Rating

Is Regeneron Pharmaceuticals, Inc. (REGN) The Most Profitable Biotech Stock To Buy Right Now?
REGN

Insider Monkey

a month ago

Is Regeneron Pharmaceuticals, Inc. (REGN) The Most Profitable Biotech Stock To Buy Right Now?

Biotech stocks slide as Marks resignation seen being negative for sector
REGN

TipRanks

a month ago

Biotech stocks slide as Marks resignation seen being negative for sector

The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals
REGN

Zacks

a month ago

The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals

REGN

MT Newswires

a month ago

Leerink Partners Adjusts PT on Regeneron Pharmaceuticals to $780 From $834, Keeps Outperform Rating

Intellia Focuses on Pipeline Development Amid Stiff Competition
REGN

Zacks

a month ago

Intellia Focuses on Pipeline Development Amid Stiff Competition

3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
REGN

Zacks

a month ago

3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space

REGN

MT Newswires

a month ago

JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $1,000 From $1,100, Maintains Overweight Rating

Regeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week Lows
REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week Lows

REGN

MT Newswires

a month ago

Regeneron, Sanofi Say Japan Grants Marketing Authorization for Dupixent

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
REGN

GlobeNewswire

a month ago

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Is Regeneron Pharmaceuticals, Inc. (REGN) a Promising Biotech Stock According to Wall Street Analysts
REGN

Insider Monkey

2 months ago

Is Regeneron Pharmaceuticals, Inc. (REGN) a Promising Biotech Stock According to Wall Street Analysts

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
REGN

GlobeNewswire

2 months ago

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
REGN

Zacks

2 months ago

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Extremely Profitable Stocks to Buy According to Analyst?
REGN

Insider Monkey

2 months ago

Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Extremely Profitable Stocks to Buy According to Analyst?

3 Reasons to Sell REGN and 1 Stock to Buy Instead
REGN

StockStory

2 months ago

3 Reasons to Sell REGN and 1 Stock to Buy Instead

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack
REGN

StockStory

2 months ago

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

Share on Social Networks: